Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Butt, Jawad H ; Fosbøl, Emil L ; Gerds, Thomas A ; Iversen, Kasper ; Bundgaard, Henning ; Bruun, Niels Eske ; Larsen, Anders R ; Petersen, Andreas ; Andersen, Paal S ; Skov, Robert L ; Østergaard, Lauge ; Havers-Borgersen, Eva ; Gislason, Gunnar H ; Torp-Pedersen, Christian ; Køber, Lars ; Olesen, Jonas B. / Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections. In: European heart journal. Cardiovascular pharmacotherapy. 2022 ; Vol. 8, No. 1. pp. 13-19.

Bibtex

@article{db4c829532f64a53ac4d123d3c0fcdae,
title = "Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections",
abstract = "AIMS: To investigate the 1-year risks of Staphylococcus aureus bacteraemia (SAB), sepsis, and pneumonia in patients who underwent percutaneous coronary intervention and were treated with ticagrelor vs. clopidogrel.METHODS AND RESULTS: In this nationwide observational cohort study, 26 606 patients who underwent urgent or emergent percutaneous coronary intervention (January 2011-December 2017) and initiated treatment with ticagrelor [N = 20 073 (75.5%); median age 64 years (25th-75th percentile 55-72 years); 74.8% men] or clopidogrel [N = 6533 (24.5%); median age 68 years (25th-75th percentile 58-77 years); 70.2% men] were identified using Danish nationwide registries. The 1-year standardized absolute risks of outcomes was calculated based on cause-specific Cox regression models, and average treatment effects between treatment groups were obtained as standardized differences in absolute 1-year risks. The absolute 1-year risk of SAB was 0.10% [95% confidence interval (CI), 0.05-0.15%] in the ticagrelor group and 0.29% (95% CI, 0.17-0.42%) in the clopidogrel group. Compared with clopidogrel, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of SAB [absolute risk difference -0.19% (95% CI, -0.32% to -0.05%), P value 0.006]. Likewise, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of sepsis [0.99% (95% CI, 0.83-1.14%) vs. 1.49% (95% CI, 1.17-1.80%); absolute risk difference -0.50% (95% CI, -0.86% to -0.14%), P value 0.007] and pneumonia [3.13% (95% CI, 2.86-3.39%) vs. 4.56% (95% CI, 4.03-5.08%); absolute risk difference -1.43% (95% CI, -2.03% to -0.82%), P value < 0.001] compared with clopidogrel.CONCLUSION: Treatment with ticagrelor was associated with a significantly lower 1-year risk of SAB, sepsis, and pneumonia compared with clopidogrel.",
author = "Butt, {Jawad H} and Fosb{\o}l, {Emil L} and Gerds, {Thomas A} and Kasper Iversen and Henning Bundgaard and Bruun, {Niels Eske} and Larsen, {Anders R} and Andreas Petersen and Andersen, {Paal S} and Skov, {Robert L} and Lauge {\O}stergaard and Eva Havers-Borgersen and Gislason, {Gunnar H} and Christian Torp-Pedersen and Lars K{\o}ber and Olesen, {Jonas B}",
note = "{\textcopyright} Published on behalf of the European Society of Cardiology. All rights reserved. {\textcopyright} The Author 2020. For permissions, please email: journals.permissions@oup.com.",
year = "2022",
month = jan,
day = "5",
doi = "10.1093/ehjcvp/pvaa099",
language = "English",
volume = "8",
pages = "13--19",
journal = "European Heart Journal - Cardiovascular Pharmacotherapy",
issn = "2055-6837",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

AU - Butt, Jawad H

AU - Fosbøl, Emil L

AU - Gerds, Thomas A

AU - Iversen, Kasper

AU - Bundgaard, Henning

AU - Bruun, Niels Eske

AU - Larsen, Anders R

AU - Petersen, Andreas

AU - Andersen, Paal S

AU - Skov, Robert L

AU - Østergaard, Lauge

AU - Havers-Borgersen, Eva

AU - Gislason, Gunnar H

AU - Torp-Pedersen, Christian

AU - Køber, Lars

AU - Olesen, Jonas B

N1 - © Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2020. For permissions, please email: journals.permissions@oup.com.

PY - 2022/1/5

Y1 - 2022/1/5

N2 - AIMS: To investigate the 1-year risks of Staphylococcus aureus bacteraemia (SAB), sepsis, and pneumonia in patients who underwent percutaneous coronary intervention and were treated with ticagrelor vs. clopidogrel.METHODS AND RESULTS: In this nationwide observational cohort study, 26 606 patients who underwent urgent or emergent percutaneous coronary intervention (January 2011-December 2017) and initiated treatment with ticagrelor [N = 20 073 (75.5%); median age 64 years (25th-75th percentile 55-72 years); 74.8% men] or clopidogrel [N = 6533 (24.5%); median age 68 years (25th-75th percentile 58-77 years); 70.2% men] were identified using Danish nationwide registries. The 1-year standardized absolute risks of outcomes was calculated based on cause-specific Cox regression models, and average treatment effects between treatment groups were obtained as standardized differences in absolute 1-year risks. The absolute 1-year risk of SAB was 0.10% [95% confidence interval (CI), 0.05-0.15%] in the ticagrelor group and 0.29% (95% CI, 0.17-0.42%) in the clopidogrel group. Compared with clopidogrel, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of SAB [absolute risk difference -0.19% (95% CI, -0.32% to -0.05%), P value 0.006]. Likewise, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of sepsis [0.99% (95% CI, 0.83-1.14%) vs. 1.49% (95% CI, 1.17-1.80%); absolute risk difference -0.50% (95% CI, -0.86% to -0.14%), P value 0.007] and pneumonia [3.13% (95% CI, 2.86-3.39%) vs. 4.56% (95% CI, 4.03-5.08%); absolute risk difference -1.43% (95% CI, -2.03% to -0.82%), P value < 0.001] compared with clopidogrel.CONCLUSION: Treatment with ticagrelor was associated with a significantly lower 1-year risk of SAB, sepsis, and pneumonia compared with clopidogrel.

AB - AIMS: To investigate the 1-year risks of Staphylococcus aureus bacteraemia (SAB), sepsis, and pneumonia in patients who underwent percutaneous coronary intervention and were treated with ticagrelor vs. clopidogrel.METHODS AND RESULTS: In this nationwide observational cohort study, 26 606 patients who underwent urgent or emergent percutaneous coronary intervention (January 2011-December 2017) and initiated treatment with ticagrelor [N = 20 073 (75.5%); median age 64 years (25th-75th percentile 55-72 years); 74.8% men] or clopidogrel [N = 6533 (24.5%); median age 68 years (25th-75th percentile 58-77 years); 70.2% men] were identified using Danish nationwide registries. The 1-year standardized absolute risks of outcomes was calculated based on cause-specific Cox regression models, and average treatment effects between treatment groups were obtained as standardized differences in absolute 1-year risks. The absolute 1-year risk of SAB was 0.10% [95% confidence interval (CI), 0.05-0.15%] in the ticagrelor group and 0.29% (95% CI, 0.17-0.42%) in the clopidogrel group. Compared with clopidogrel, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of SAB [absolute risk difference -0.19% (95% CI, -0.32% to -0.05%), P value 0.006]. Likewise, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of sepsis [0.99% (95% CI, 0.83-1.14%) vs. 1.49% (95% CI, 1.17-1.80%); absolute risk difference -0.50% (95% CI, -0.86% to -0.14%), P value 0.007] and pneumonia [3.13% (95% CI, 2.86-3.39%) vs. 4.56% (95% CI, 4.03-5.08%); absolute risk difference -1.43% (95% CI, -2.03% to -0.82%), P value < 0.001] compared with clopidogrel.CONCLUSION: Treatment with ticagrelor was associated with a significantly lower 1-year risk of SAB, sepsis, and pneumonia compared with clopidogrel.

UR - http://www.scopus.com/inward/record.url?scp=85123325569&partnerID=8YFLogxK

U2 - 10.1093/ehjcvp/pvaa099

DO - 10.1093/ehjcvp/pvaa099

M3 - Journal article

C2 - 32750138

VL - 8

SP - 13

EP - 19

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

SN - 2055-6837

IS - 1

ER -

ID: 60682489